Krystexxa

Active Ingredient(s): Pegloticase
FDA Approved: * September 14, 2010
Pharm Company: * SAVIENT PHARMS
Category: Gout

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Krystexxa Overview

Pegloticase (trade name Krystexxa) is a medication for the treatment of severe, treatment-refractory, chronic gout. It is a third line treatment in those in whom other treatments are not tolerated.[1] The drug is administered by infusion intravenously. It was developed by Savient Pharmaceuticals.[2][3] In September 2010, the FDA approved pegloticase for marketing in the United States after two clinical trials demonstrated the drug lowered uric a...

Read more Krystexxa Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Pegloticase

Recent Krystexxa Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Pegloticase
  • Injection: 8mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Krystexxa: (3 results)

Sorted by National Drug Code
  • 54396-801 Krystexxa 8 mg/ml Intravenous Injection, Solution by Savient Pharmaceuticals, Inc.
  • 60809-801 Krystexxa 8 mg/ml Intravenous Injection, Solution by Crealta Pharmaceuticals LLC
  • 75987-080 Krystexxa 8 mg/ml Intravenous Injection, Solution by Horizon Pharma Inc.

Other drugs which contain Pegloticase or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 18 January 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA